TY - JOUR
T1 - Prospective validation of the RAPID clinical risk prediction score in adult patients with pleural infection
T2 - The PILOT study
AU - Corcoran, John P.
AU - Psallidas, Ioannis
AU - Gerry, Stephen
AU - Piccolo, Francesco
AU - Koegelenberg, Coenraad F.
AU - Saba, Tarek
AU - Daneshvar, Cyrus
AU - Fairbairn, Ian
AU - Heinink, Richard
AU - West, Alex
AU - Stanton, Andrew E.
AU - Holme, Jayne
AU - Kastelik, Jack A.
AU - Steer, Henry
AU - Downer, Nicola J.
AU - Haris, Mohammed
AU - Baker, Emma H.
AU - Everett, Caroline F.
AU - Pepperell, Justin
AU - Bewick, Thomas
AU - Yarmus, Lonny
AU - Maldonado, Fabien
AU - Khan, Burhan
AU - Hart-Thomas, Alan
AU - Hands, Georgina
AU - Warwick, Geoffrey
AU - de Fonseka, Duneesha
AU - Hassan, Maged
AU - Munavvar, Mohammed
AU - Guhan, Anur
AU - Shahidi, Mitra
AU - Pogson, Zara
AU - Dowson, Lee
AU - Popowicz, Natalia D.
AU - Saba, Judith
AU - Ward, Neil R.
AU - Hallifax, Rob J.
AU - Dobson, Melissa
AU - Shaw, Rachel
AU - Hedley, Emma L.
AU - Sabia, Assunta
AU - Robinson, Barbara
AU - Collins, Gary S.
AU - Davies, Helen E.
AU - Yu, Ly Mee
AU - Miller, Robert F.
AU - Maskell, Nick A.
AU - Rahman, Najib M.
N1 - Funding Information:
Conflict of interest: J.P. Corcoran reports grants from the UK Medical Research Council (MRC; grant number G1001128), during the conduct of the study. I. Psallidas reports grants from the UK MRC (grant number G1001128), during the conduct of the study, as well as grants and personal fees from the European Respiratory Society (ERS), outside the submitted work. S. Gerry has nothing to disclose. F. Piccolo has nothing to disclose. C.F. Koegelenberg has nothing to disclose. T. Saba has nothing to disclose. C. Daneshvar has nothing to disclose. I. Fairbairn has nothing to disclose. R. Heinink has nothing to disclose. A. West has nothing to disclose. A.E. Stanton has nothing to disclose. J. Holme has nothing to disclose. J.A. Kastelik has nothing to disclose. H. Steer has nothing to disclose. N.J. Downer has nothing to disclose. M. Haris has nothing to disclose. E.H. Baker has nothing to disclose. C.F. Everett has nothing to disclose. J. Pepperell has nothing to disclose. T. Bewick has nothing to disclose. L. Yarmus has nothing to disclose. F. Maldonado has nothing to disclose. B. Khan has nothing to disclose. A. Hart-Thomas has nothing to disclose. G. Hands has nothing to disclose. G. Warwick has nothing to disclose. D. De Fonseka has nothing to disclose. M. Hassan reports grants from the UK MRC (grant number G1001128), during the conduct of the study. M. Munavvar has nothing to disclose. A. Guhan has nothing to disclose. M. Shahidi has nothing to disclose. Z. Pogson has nothing to disclose. L. Dowson has nothing to disclose. N.D. Popowicz has nothing to disclose. J. Saba has nothing to disclose. N.R. Ward has nothing to disclose. R.J. Hallifax reports grants from the UK MRC (grant number G1001128), during the conduct of the study. M. Dobson reports grants from the UK MRC (grant number G1001128), during the conduct of the study. R. Shaw reports grants from the UK MRC (grant number G1001128), during the conduct of the study. E.L. Hedley reports grants from the UK MRC (grant number G1001128), during the conduct of the study. A. Sabia reports grants from the UK MRC (grant number G1001128), during the conduct of the study. B. Robinson reports grants from the UK MRC (grant number G1001128), during the conduct of the study. G.S. Collins has nothing to disclose. H.E. Davies has nothing to disclose. L-M. Yu has nothing to disclose. R.F. Miller has nothing to disclose. N.A. Maskell has nothing to disclose. N.M. Rahman reports grants from the UK MRC (grant number G1001128), during the conduct of the study, as well as personal fees from the UK National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, outside the submitted work.
Funding Information:
Support statement: The study was funded by the UK Medical Research Council (MRC; grant number G1001128). N.M. Rahman is funded by the UK National Institute for Health Research (NIHR) Oxford Biomedical Research Centre Programme. None of the funders had any influence on study design, delivery, analysis, or manuscript preparation. Funding information for this article has been deposited with the Crossref Funder Registry.
Publisher Copyright:
Copyright © ERS 2020
PY - 2020/11
Y1 - 2020/11
N2 - Background: Over 30% of adult patients with pleural infection either die and/or require surgery. There is no robust means of predicting at baseline presentation which patients will suffer a poor clinical outcome. A validated risk prediction score would allow early identification of high-risk patients, potentially directing more aggressive treatment thereafter. Objectives: To prospectively assess a previously described risk score (the RAPID (Renal (urea), Age, fluid Purulence, Infection source, Dietary (albumin)) score) in adults with pleural infection. Methods: Prospective observational cohort study that recruited patients undergoing treatment for pleural infection. RAPID score and risk category were calculated at baseline presentation. The primary outcome was mortality at 3 months; secondary outcomes were mortality at 12 months, length of hospital stay, need for thoracic surgery, failure of medical treatment and lung function at 3 months. Results: Mortality data were available in 542 out of 546 patients recruited (99.3%). Overall mortality was 10% at 3 months (54 out of 542) and 19% at 12 months (102 out of 542). The RAPID risk category predicted mortality at 3 months. Low-risk mortality (RAPID score 0-2): five out of 222 (2.3%, 95% CI 0.9 to 5.7%); medium-risk mortality (RAPID score 3-4): 21 out of 228 (9.2%, 95% CI 6.0 to 13.7%); and high-risk mortality (RAPID score 5-7): 27 out of 92 (29.3%, 95% CI 21.0 to 39.2%). C-statistics for the scores at 3 months and 12 months were 0.78 (95% CI 0.71-0.83) and 0.77 (95% CI 0.72-0.82), respectively. Conclusions: The RAPID score stratifies adults with pleural infection according to increasing risk of mortality and should inform future research directed at improving outcomes in this patient population.
AB - Background: Over 30% of adult patients with pleural infection either die and/or require surgery. There is no robust means of predicting at baseline presentation which patients will suffer a poor clinical outcome. A validated risk prediction score would allow early identification of high-risk patients, potentially directing more aggressive treatment thereafter. Objectives: To prospectively assess a previously described risk score (the RAPID (Renal (urea), Age, fluid Purulence, Infection source, Dietary (albumin)) score) in adults with pleural infection. Methods: Prospective observational cohort study that recruited patients undergoing treatment for pleural infection. RAPID score and risk category were calculated at baseline presentation. The primary outcome was mortality at 3 months; secondary outcomes were mortality at 12 months, length of hospital stay, need for thoracic surgery, failure of medical treatment and lung function at 3 months. Results: Mortality data were available in 542 out of 546 patients recruited (99.3%). Overall mortality was 10% at 3 months (54 out of 542) and 19% at 12 months (102 out of 542). The RAPID risk category predicted mortality at 3 months. Low-risk mortality (RAPID score 0-2): five out of 222 (2.3%, 95% CI 0.9 to 5.7%); medium-risk mortality (RAPID score 3-4): 21 out of 228 (9.2%, 95% CI 6.0 to 13.7%); and high-risk mortality (RAPID score 5-7): 27 out of 92 (29.3%, 95% CI 21.0 to 39.2%). C-statistics for the scores at 3 months and 12 months were 0.78 (95% CI 0.71-0.83) and 0.77 (95% CI 0.72-0.82), respectively. Conclusions: The RAPID score stratifies adults with pleural infection according to increasing risk of mortality and should inform future research directed at improving outcomes in this patient population.
UR - http://www.scopus.com/inward/record.url?scp=85096946899&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85096946899&partnerID=8YFLogxK
U2 - 10.1183/13993003.00130-2020
DO - 10.1183/13993003.00130-2020
M3 - Review article
C2 - 32675200
AN - SCOPUS:85096946899
SN - 0903-1936
VL - 56
JO - European Respiratory Journal, Supplement
JF - European Respiratory Journal, Supplement
IS - 5
M1 - 2000130
ER -